Navigation Links
Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
Date:8/21/2008


Satisfies initial listing requirements with NASDAQ; Stock Symbol 'OGXI'

Implements immediate restructuring program, which extends cash runway

while focusing on clinical pipeline programs

BOTHELL, WA, Aug. 21 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.) (NASDAQ: OGXI) (the "Company") announced that the Company has completed its acquisition of OncoGenex Technologies and NASDAQ has approved the commencement of trading in Company's common stock on The NASDAQ Capital Market under the stock symbol 'OGXI' effective today, August 21, 2008, when the market opens. Prior to completing the acquisition, the Company changed its name to OncoGenex Pharmaceuticals, amended its authorized share capital and effected a one-for-eighteen reverse stock split.

"Clearly the shareholders of both companies, Sonus Pharmaceuticals and OncoGenex Technologies, strongly favored this transaction and our efforts to maintain a NASDAQ listing," said Scott Cormack, President and Chief Executive Officer of OncoGenex Pharmaceuticals. "On August 19th, a very strong percentage of Sonus' shareholders voted in favor of the transaction and voted in favor of a reverse stock split. One hundred percent of OncoGenex Technologies' shareholders voted in favor of the transaction."

Additionally, as announced on August 20th, the Company has implemented cost-saving measures to preserve cash while focusing on its highest potential product development programs. The Company will reduce workforce by approximately 49%. As a result of these actions, the Company will incur approximately $1.2 million in charges in the third quarter of 2008, associated with employee severance costs. Management estimates that
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
2. Sonus Pharmaceuticals Receives Favorable NASDAQ Decision
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Baylor Research Institute (BRI) at ... Institute (TGen) in Phoenix, AZ , ... detection and treatments for patients with a broad range of ... to new clinical trials and access to technology to drive ... bench to bedside across Baylor Scott & White ...
(Date:5/21/2015)... Seventh Wave Laboratories, a consulting-based contract ... pharmaceutical products and medical devices, announced the purchase of ... 50,000 sq. ft. building more than three times the ... Facility renovations will begin immediately and the gradual transition ... in September. , “We are excited about this ...
(Date:5/21/2015)... , May 21, 2015  Susan Hedstrom, Executive ... a nonprofit organization dedicated to supporting research to ... (PWS), announced today that FPWR has received the ... Irina Shaulov contributed $1 million in support ... "Our gift ...
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3
... Contaminations of cell cultures show severe problems in the research ... turns here particularly to the prevention , ... that develop substances for therapeutic applications ... focus., Endotoxins (Lipopolysaccharides, LPS) are biologically active, ...
... Amino Acids, RP-HPLC, Precolumn derivatisation, o-Phthalaldehyde (OPA), 2-Mercaptopropionic acid, ... Introduction: , ... light in the UV/visible spectrum. In order to increase sensitivity, ... the amino acids react with a precursor to yield ...
... and specific PCR on any thermal cycler , ... unrivaled performance of , HotStarTaq Plus DNA Polymerase with ... thermal cycler. , , ... Ultrafast hot-start PCR time savings of up to 75%, ...
Cached Biology Technology:Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 2Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 3Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 4Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 5Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 6Endotoxins and their Relevance in R&D ApplicationsLPS Detection & Removal Methods 7ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION 2ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION 3QIAGEN Fast Cycling PCR Kit 2QIAGEN Fast Cycling PCR Kit 3QIAGEN Fast Cycling PCR Kit 4
(Date:5/11/2015)... 11, 2015  Synaptics Incorporated (NASDAQ: SYNA ... today announced the appointment of Wajid Ali ... Officer, reporting to Rick Bergman , President ... Financial Officer, Kathleen Bayless , who announced ... Mr. Ali brings extensive financial management expertise to ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/8/2015)... SAN JOSE, Calif. , May 8, 2015 ... human interface solutions, today announced that members of the executive ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Westin Waterfront Hotel in Boston, MA ... Date: May 27, 2015 Time: 2:45pm ET Location: The New ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... For Immediate Release The Scripps Research Institute and ... Medicine have been awarded approximately $7.5 million over five ... drug candidates for the treatment of nicotine dependence, and ... million will go to Scripps Research, $2.5 million to ...
... of Guelph researchers have finally figured out why female ... nothing to do with genes and everything to do ... "Their behaviour is overwhelmingly influenced by opportunity," said ... professor Andrew McAdam and a team of researchers from ...
... what goes missing in human cells when the gene that ... Johns Hopkins scientists have discovered a potential strategy for therapy. ... snippets known as microRNAs is dramatically reduced in human pancreatic ... a study published Dec. 15 in Genes and Development ...
Cached Biology News:Team awarded $7.5 million to identify potential drug candidates to treat nicotine addiction 2Team awarded $7.5 million to identify potential drug candidates to treat nicotine addiction 3Opportunity leads to promiscuity among squirrels, study finds 2Missing molecules hold promise of therapy for pancreatic cancer 2Missing molecules hold promise of therapy for pancreatic cancer 3
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
...
...
Recombinant Rat Fas Ligand/TNFSF6...
Biology Products: